Case Study: Pharma 4.0™ Transformation Office – Webinar Q&A

Aida Ballester
Karen Frances Medroa
iSpeak

The pharmaceutical industry is at a crossroads. Legacy systems, manual workflows, and paper-heavy processes are slowing down innovation.

During a recent ISPE webinar, “Case Study: Pharma 4.0 Transformation Office,” Aida Ballester and Karen Medroa shared a compelling case study showing how a global transformation project management office (PMO) helped a leading pharma company make the leap into Industry 4.0.

They broke down the transformation journey into three pillars of Pharma 4.0 PMO success:

  1. Project and Program Delivery Management: Transforming complexity into clarity
  2. Governance and Collaboration: Empowering transformation with governance and agile value delivery
  3. Communication and Change Enablement: Turning stakeholders into change champions

The following blog post delves deeper into the most insightful Q&A moments from the webinar, with the real-world challenges, doubts, and success factors that resonated most with the webinar audience.

How did you adapt the way of working to support project delivery in such a complex environment?

Ballester and Medroa: We focused on aligning  people, processes, and tools. The goal wasn’t to standardize everything at once, but to gradually introduce a consistent way of working.

We didn’t migrate all ongoing projects at the same time—instead, we applied the new methodology in stages, while ensuring that new projects started with the updated approach.

We also supported teams through a mix of  theoretical training, coaching, and hands-on support  from our PMOs, helping them adopt best practices and manage projects more effectively.

Why was governance such a key focus in this transformation?

Ballester and Medroa: Governance is always important—but in this case, it was critical. We were dealing with projects already in motion, different levels of maturity across units, and multiple ongoing initiatives.

Without a strong governance model, adoption becomes much harder.

Collaboration also played a big role—it allowed us to learn from more advanced initiatives and avoid reinventing the wheel. It was about creating alignment, not uniformity.

What change management methodology did you use in this project?

Ballester and Medroa: We used a combination of well-known models like Kotter and ADKAR, but we also applied our own internal framework, which fits within broader methodologies.

Our approach is structured around three key moments:

Prepare for change, drive the change, and sustain the change.

This helped us guide the client whose case study we discussed during this webinar through the full journey—from readiness and stakeholder alignment to adoption and long-term reinforcement.

How did you prioritize initiatives within the transformation portfolio?

Ballester and Medroa: We used a maturity assessment and benefit analysis to identify high-impact areas. Initiatives were prioritized based on strategic relevance, feasibility, and readiness, ensuring a balance between quick wins and long-term value.

What key performance indicators (KPIs) were most critical to track progress and adoption?

Ballester and Medroa: We tracked 215 strategic KPIs, including cycle time reduction, adoption rates of digital tools, training completion, and milestone delivery. These indicators helped measure both operational impact and cultural shift.

What would you do differently if starting the transformation today?

Ballester and Medroa: We would invest even more in early stakeholder engagement and readiness assessments. Starting with a stronger baseline of digital maturity could accelerate adoption and reduce initial resistance.

How did you transfer lessons learned from other industries into the Pharma 4.0 context?

Ballester and Medroa: We leveraged best practices from manufacturing and tech sectors, especially around agile governance and lean innovation. These insights helped us tailor solutions to pharma’s regulatory and operational constraints.

Conclusion

Pharma’s digital transformation isn’t just about technology, it’s about people, processes, and mindset. As Ballester and Medroa have highlighted, the PMO plays a crucial role in bridging strategy and execution, ensuring that innovation truly delivers value.

The Q&A made one thing clear: there’s no one-size-fits-all approach, but with the right governance, collaboration, and change enablement, transformation becomes not only possible, but sustainable.

ISPE members: Watch the webinar to learn more 

Not yet an ISPE member? Join today.  

Disclaimer

iSpeak Blog posts provide an opportunity for the dissemination of ideas and opinions on topics impacting the pharmaceutical industry. Ideas and opinions expressed in iSpeak Blog posts are those of the author(s) and publication thereof does not imply endorsement by ISPE.


Submit Your Best Content to ISPE

ISPE’s official blog, iSpeak accepts contributions from our Members and professionals in the pharma industry.  

What We Look For 

References